Xencor (NASDAQ:XNCR) Now Covered by Analysts at William Blair

William Blair assumed coverage on shares of Xencor (NASDAQ:XNCR - Free Report) in a research note published on Monday morning, Marketbeat.com reports. The firm issued an outperform rating on the biopharmaceutical company's stock. William Blair also issued estimates for Xencor's Q1 2025 earnings at ($0.84) EPS, Q2 2025 earnings at ($0.82) EPS, Q3 2025 earnings at ($0.81) EPS, Q4 2025 earnings at ($0.80) EPS, FY2025 earnings at ($3.27) EPS, FY2026 earnings at ($3.15) EPS, FY2027 earnings at ($3.01) EPS and FY2028 earnings at ($3.05) EPS.

Several other analysts have also recently weighed in on XNCR. StockNews.com cut Xencor from a "hold" rating to a "sell" rating in a report on Friday, March 14th. Wells Fargo & Company decreased their price target on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $33.86.

Xencor Stock Performance

Shares of XNCR stock traded down $0.03 during trading on Monday, reaching $10.84. 618,486 shares of the company's stock were exchanged, compared to its average volume of 627,814. Xencor has a twelve month low of $7.16 and a twelve month high of $27.24. The firm's fifty day moving average price is $11.99 and its 200-day moving average price is $18.55. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $763.81 million, a PE ratio of -3.39 and a beta of 0.90.

Xencor (NASDAQ:XNCR - Get Free Report) last announced its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.19. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The business had revenue of $52.79 million during the quarter, compared to the consensus estimate of $17.14 million. As a group, sell-side analysts anticipate that Xencor will post -3.68 EPS for the current year.

Hedge Funds Weigh In On Xencor

Several institutional investors and hedge funds have recently added to or reduced their stakes in XNCR. Barclays PLC grew its position in Xencor by 100.7% during the 3rd quarter. Barclays PLC now owns 155,568 shares of the biopharmaceutical company's stock worth $3,128,000 after acquiring an additional 78,066 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Xencor by 1.2% during the third quarter. Geode Capital Management LLC now owns 1,455,350 shares of the biopharmaceutical company's stock worth $29,273,000 after purchasing an additional 17,658 shares during the last quarter. Sanctuary Advisors LLC bought a new position in Xencor in the 3rd quarter valued at approximately $540,000. JPMorgan Chase & Co. raised its holdings in Xencor by 2.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 130,354 shares of the biopharmaceutical company's stock valued at $2,621,000 after buying an additional 3,635 shares during the last quarter. Finally, GAMMA Investing LLC boosted its position in Xencor by 31.0% during the 4th quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company's stock worth $49,000 after buying an additional 508 shares during the period.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.